Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProPhase LabsPRPH -4.52% Days Sales Outstanding is 139.27 as of Jun. 2026, which is 19% above its 10-year median of 117.35. The stock has 6 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, ProPhase Labs ranks worse than 96.55% on this metric.
ProPhase Labs's average Accounts Receivable for the
three
months ended in Jun. 2026 was $1.54 Mil. ProPhase Labs's Revenue for the
three
months ended in Jun. 2026 was $1.01 Mil.
Hence, ProPhase Labs's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 139.27.
The historical rank and industry rank for ProPhase Labs's Days Sales Outstanding or its related term are showing as below:
PRPH'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.32 Med: 117.35 Max: 2010.44
Current: 550.56
During the past 13 years, ProPhase Labs's highest Days Sales Outstanding was 2010.44. The lowest was 47.32. And the median was 117.35.
PRPH's Days Sales Outstanding is ranked worse than 96.55% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.79
vs PRPH: 550.56
ProPhase Labs's Days Sales Outstanding
declined
from Jun. 2025 (1,474.12) to Jun. 2026 (139.27).
ProPhase Labs (OTCPK:PRPH) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
ProPhase Labs Days Sales Outstanding Related Terms
ProPhase Labs Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for ProPhase Labs's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRPH vs NOTVQ, NSTM, FUNI: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, ProPhase Labs's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProPhase Labs Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where ProPhase Labs's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 139.27 mean?
ProPhase Labs (PRPH) has a Days Sales Outstanding of 139.27 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ProPhase Labs and its competitors. This is 19% above median its historical median of 117.35. Over the past decade, ProPhase Labs' Days Sales Outstanding has ranged from 47.32 to 2,010.44. According to the industry distribution chart, ProPhase Labs ranks #196 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 96.6%.
Is ProPhase Labs' Days Sales Outstanding too high?
ProPhase Labs' current Days Sales Outstanding of 139.27 is 19% above median its 10-year median of 117.35. Over the past 10 years, this metric has ranged from a low of 47.32 to a high of 2,010.44. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.79. ProPhase Labs' value of 139.27 is 105.4% above this industry median. Based on the distribution chart, ProPhase Labs ranks #196 out of 203 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does ProPhase Labs' Days Sales Outstanding compare to NOTVQ and NSTM?
According to the Medical Diagnostics & Research industry distribution chart, ProPhase Labs ranks #196 out of 203 companies for Days Sales Outstanding. This places ProPhase Labs in the lower half of its industry. The industry median Days Sales Outstanding is 67.79. ProPhase Labs' value of 139.27 is 105.4% above this benchmark. Historically, ProPhase Labs' own Days Sales Outstanding has ranged from 47.32 to 2,010.44 over the past decade. While the company's 10-year median is 117.35 vs. the industry median of 67.79, ProPhase Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.79, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProPhase Labs's current Days Sales Outstanding of 139.27 is 105.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ProPhase Labs and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProPhase Labs's current Days Sales Outstanding is 139.27, which is 19% above median its own 10-year median of 117.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProPhase Labs stock overvalued right now?
Based on GuruFocus' analysis, ProPhase Labs (PRPH) is currently considered Possible Value Trap. The stock's GF Value™ is $0.59, compared to a current price of $0.02 — trading 96.4% below its estimated fair value. The current Days Sales Outstanding is 139.27, which is 19% above median its 10-year median of 117.35 and 105.4% above the Medical Diagnostics & Research industry median of 67.79. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For ProPhase Labs (PRPH), the current Days Sales Outstanding is 139.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProPhase Labs Inc oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing. It offer whole genome sequencing and related services. It maintain two operating segments: diagnostic services (which includes its COVID-19 and other diagnostic testing services) and consumer products. It generates majority of revenue from consumer products segment which engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRPH has been successfully added to your 
